Barclays analyst Gena Wang raised the firm’s price target on Vir Biotechnology (VIR) to $31 from $26 and keeps an Overweight rating on the shares following the Q4 report.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Transformative Year: Earnings Call Insights
- Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology
- Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis
- Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Vir Biotechnology Reports 2024 Financial Results and Strategic Advances